Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagen...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6017 |
| _version_ | 1826588210122194944 |
|---|---|
| author | Tatiana Ivanovna Romantsova Nadezhda Viktorovna Maksimova |
| author_facet | Tatiana Ivanovna Romantsova Nadezhda Viktorovna Maksimova |
| author_sort | Tatiana Ivanovna Romantsova |
| collection | DOAJ |
| description | Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagents of this class produce side effects (increased body mass, hypoglycemia, resistance to therapy, etc.) attributable to excess stimulation of insulinsecretion. Glimepiride is as efficient as traditionally used sulfonylureas but causes a smaller rise in insulin secretion. Sulfonylurea receptors showlower affinity for glimepiride than for glibenclamide. Formation and dissociation of glimepiride-receptor complexes occur faster than those of glibenclamide-receptor complexes. In addition, therapeutic effect of glimepiride was shown to be associated with improved insulin sensitivity. It is concludedthat glimepiride is an efficacious agent for the treatment of type 2 diabetes. |
| first_indexed | 2024-03-08T15:21:58Z |
| format | Article |
| id | doaj.art-033d27e0f2a149c69bf313f03c494de0 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2025-03-14T16:37:42Z |
| publishDate | 2010-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-033d27e0f2a149c69bf313f03c494de02025-02-21T09:29:27ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-03-01131505410.14341/2072-0351-60175975Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepirideTatiana Ivanovna Romantsova0Nadezhda Viktorovna Maksimova1I.M. Sechenov Moscow Medical AcademyI.M. Sechenov Moscow Medical AcademyType 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagents of this class produce side effects (increased body mass, hypoglycemia, resistance to therapy, etc.) attributable to excess stimulation of insulinsecretion. Glimepiride is as efficient as traditionally used sulfonylureas but causes a smaller rise in insulin secretion. Sulfonylurea receptors showlower affinity for glimepiride than for glibenclamide. Formation and dissociation of glimepiride-receptor complexes occur faster than those of glibenclamide-receptor complexes. In addition, therapeutic effect of glimepiride was shown to be associated with improved insulin sensitivity. It is concludedthat glimepiride is an efficacious agent for the treatment of type 2 diabetes.https://www.dia-endojournals.ru/jour/article/view/6017treatment of type 2 diabetessulfonylureasglimepirideinsulin secretioninsulin sensitivity |
| spellingShingle | Tatiana Ivanovna Romantsova Nadezhda Viktorovna Maksimova Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride Сахарный диабет treatment of type 2 diabetes sulfonylureas glimepiride insulin secretion insulin sensitivity |
| title | Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_full | Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_fullStr | Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_full_unstemmed | Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_short | Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_sort | optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| topic | treatment of type 2 diabetes sulfonylureas glimepiride insulin secretion insulin sensitivity |
| url | https://www.dia-endojournals.ru/jour/article/view/6017 |
| work_keys_str_mv | AT tatianaivanovnaromantsova optimizationoftherapyoftype2diabetesmellituswiththeoralhypoglycemicagentglimepiride AT nadezhdaviktorovnamaksimova optimizationoftherapyoftype2diabetesmellituswiththeoralhypoglycemicagentglimepiride |